TY - JOUR
T1 - Development of nano structured graphene oxide incorporated dexamethasone with enhanced dissolution
AU - Islam, Mohammad Saiful
AU - Mitra, Somenath
N1 - Funding Information:
This research work was supported by a funding agency called National Institute of Environmental Health Sciences (NIEHS) under Grant No. R01ES023209 . The reported works findings, opinions, recommendations, and conclusions are those of the author(s) and do not reflect the NIEHS. Additionally, we would like to acknowledge the funding from the Ida C. Fritts Chair at New Jersey Institute of Technology . Finally, we acknowledge the Otto York Center of Environmental Engineering and Science for allowing us to use the instrumentation for characterization.
Publisher Copyright:
© 2022 The Authors
PY - 2022/3
Y1 - 2022/3
N2 - We present the development of nanographene oxide (nGO) incorporated dexamethasone (DXM) composites (DXM-nGO) with enhanced aqueous solubility. Antisolvent precipitation was used for successful incorporation of nGO into DXM, a popular COVID-19 drug. The study focuses on morphology and dissolution performance of the formulated DXM-nGO, which were characterized using scanning electron microscopy (SEM), Raman spectroscopy, X-ray diffraction (XRD), Differential scanning calorimetry (DSC) and Thermogravimetric analysis (TGA). In vitro dissolution profile showed that for a DXM-nGO containing 0.5% nGO showed that time for 50% dissolution (T50) dropped from 39 min to 24 min, while time for 80% dissolution (T80) went from not dissolved state to 56 min for the same composite. In general, the nGO incorporation into DXM showed enhanced solubility, and in vitro dissolution data suggest that the nGO may be a candidate for successful bioavailability improvement.
AB - We present the development of nanographene oxide (nGO) incorporated dexamethasone (DXM) composites (DXM-nGO) with enhanced aqueous solubility. Antisolvent precipitation was used for successful incorporation of nGO into DXM, a popular COVID-19 drug. The study focuses on morphology and dissolution performance of the formulated DXM-nGO, which were characterized using scanning electron microscopy (SEM), Raman spectroscopy, X-ray diffraction (XRD), Differential scanning calorimetry (DSC) and Thermogravimetric analysis (TGA). In vitro dissolution profile showed that for a DXM-nGO containing 0.5% nGO showed that time for 50% dissolution (T50) dropped from 39 min to 24 min, while time for 80% dissolution (T80) went from not dissolved state to 56 min for the same composite. In general, the nGO incorporation into DXM showed enhanced solubility, and in vitro dissolution data suggest that the nGO may be a candidate for successful bioavailability improvement.
KW - Antisolvent precipitation
KW - Bioavailability
KW - COVID-19 drug
KW - Dexamethasone
KW - Enhanced solubility
KW - In vitro dissolution
UR - http://www.scopus.com/inward/record.url?scp=85124291387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124291387&partnerID=8YFLogxK
U2 - 10.1016/j.colcom.2022.100599
DO - 10.1016/j.colcom.2022.100599
M3 - Article
AN - SCOPUS:85124291387
SN - 2215-0382
VL - 47
JO - Colloids and Interface Science Communications
JF - Colloids and Interface Science Communications
M1 - 100599
ER -